Bio-Path (NASDAQ:BPTH – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, March 6th. Analysts expect Bio-Path to post earnings of ($0.37) per share for the quarter.
Bio-Path Trading Up 8.6 %
BPTH opened at $0.18 on Thursday. The company has a 50 day moving average of $0.82 and a two-hundred day moving average of $0.92. Bio-Path has a 52-week low of $0.12 and a 52-week high of $7.67.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on shares of Bio-Path in a report on Saturday, February 22nd. They set a “sell” rating for the company.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Read More
- Five stocks we like better than Bio-Path
- How Technical Indicators Can Help You Find Oversold Stocks
- Buffett’s on the Sidelines – Should You Follow?
- What Are Dividend Achievers? An Introduction
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- P/E Ratio Calculation: How to Assess Stocks
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
